Bahrami Shabnam, Babaei Nahid, Esmaeili Gouvarchin Ghaleh Hadi, Mohajeri Borazjani Jaleh, Farzanehpour Mahdieh
Department of Molecular Cell Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran.
Applied Virology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Front Mol Biosci. 2024 Oct 3;11:1456053. doi: 10.3389/fmolb.2024.1456053. eCollection 2024.
Ulcerative colitis (UC), a common gastrointestinal disorder in affluent nations, involves chronic intestinal mucosal inflammation. This research investigated the effects of combined probiotic treatment of (L. casei) and mesalazine on disease activity index and inflammatory factors in the UC model.
20 male BALB/c mice were utilized and divided into four groups. To induce UC, all groups received 100 μL of 4% acetic acid (AA) intra-rectally. The first group received phosphate-buffered saline (PBS) (as a control group), the second group was treated with L. casei, the third group was treated with mesalazine and, the fourth group was treated with L. casei and mesalazine. Treatment with L. Casei and mesalazine commenced after the manifestation of symptoms resulting from UC induction. Finally, the mice were euthanized and the disease activity index, myeloperoxidase activity, nitric oxide rate, cytokines level (IL-1β, IL-6, TNF-α) and, gene expression (iNOS, COX-2, and cytokines) were evaluated.
The combined treatment of L. casei and mesalazine led to a significant decrease in the levels of NO, MPO and inflammatory cytokines. In addition, the expression of cytokines, iNOS and COX-2 genes decreased in mice treated with the combination.
This study shows that combined treatment of L. casei and mesalazine improves of experimental UC, which can be attributed to the anti-inflammatory properties of L. casei and mesalazine. In conclusion, this combination therapy can be considered a suitable option for the management of UC.
溃疡性结肠炎（UC）是富裕国家常见的胃肠道疾病，涉及慢性肠道黏膜炎症。本研究调查了联合益生菌（干酪乳杆菌）和柳氮磺胺吡啶治疗对UC模型疾病活动指数和炎症因子的影响。
使用20只雄性BALB/c小鼠，分为四组。为诱导UC，所有组均经直肠给予100μL 4%乙酸（AA）。第一组接受磷酸盐缓冲盐水（PBS）（作为对照组），第二组用干酪乳杆菌治疗，第三组用柳氮磺胺吡啶治疗，第四组用干酪乳杆菌和柳氮磺胺吡啶联合治疗。在UC诱导出现症状后开始用干酪乳杆菌和柳氮磺胺吡啶进行治疗。最后，对小鼠实施安乐死并评估疾病活动指数、髓过氧化物酶活性、一氧化氮水平、细胞因子水平（IL-1β、IL-6、TNF-α）以及基因表达（诱导型一氧化氮合酶、环氧化酶-2和细胞因子）。
干酪乳杆菌和柳氮磺胺吡啶联合治疗导致NO、MPO和炎症细胞因子水平显著降低。此外，联合治疗的小鼠中细胞因子、诱导型一氧化氮合酶和环氧化酶-2基因的表达下降。
本研究表明，干酪乳杆菌和柳氮磺胺吡啶联合治疗可改善实验性UC，这可归因于干酪乳杆菌和柳氮磺胺吡啶的抗炎特性。总之，这种联合疗法可被认为是治疗UC的合适选择。
